We are delighted to announce that Elosulfase alfa (Vimizim®) has been recommended by NICE (National Institute for Health and Care Excellence) for treating MPS IVA.

Approximately 6% of the population is affected by a rare disease. The diagnostic odyssey is significant, and patients and their families can often be left waiting years for a confirmed diagnosis.

If you missed our latest webinar on the changing landscape of Highly Specialised Technologies in the UK it’s not too late to catch up.